Il Dong Pharmaceutical Co., Ltd.

Ildong Pharm Co., Ltd.

Idience Co., Ltd.

Ildong Bioscience Co., Ltd.

Jae-Hoon Kang

Hong-Sub Lee

Sun-Young Park

Kyung-Sun Kim

Dong-Keun Song

Yoon-Suk Lee

Chang-Hee Hong

Kyung-Mi An

Jin-Ah Jeong

Dae-Jung Kang

Yong-Sung Kim

Jeong-Geun Kim

Seung-Hun Lee

Yong-Don Yun

Joon-Tae Park

Hyuk Sang Kwon

Hyo-Jung Song

Seong Beom Kim

Sung-Wook Kwon

Jong-Hyuk Im

Hyei Yoon Jung

Hey-Min Hwang

Ji-Hye Choi

Kyeo-Jin Kim

Jeong-Guen Kim

Shuo-Lin Cui

Hyun-Jung Kwak

Seok Woo Yang

Young-Min Lee

Hyuk-Sang Kwon

Jong-Hee Ko

Moo-Soo Jang

Seung-Woo Yu

Dong-Sik Yu

Kee-Won Kim

Dae Jung Kang

Hyun-Jung Jung

Tae-Yoon Kim

Seok-Woo Yang

Hyei-Yoon Jung

The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Isoxazole derivatives as nuclear receptor agonists and uses thereof

The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.

Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused

Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.

Phenyl propionic acid derivatives and uses thereof

The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.

Phthalazinone derivatives and manufacturing process thereof

The present invention relates to heat-killedconjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killedconjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.

RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases

The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (I) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.

Method for treating eye diseases with a fusion protein of a tissue-penetrating peptide and anti-vascular endothelial growth factor

The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).

The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.

Pharmaceutical composition containing, as active ingredient, fusion protein in which tumor-penetrating peptide and anti-angiogenesis agent are fused, for preventing and treating cancer or angiogenesis-related diseases

The present invention relates to a functional hydrated hyaluronic acid and a method for producing 5generation coated lactic acid bacteria having excellent intestinal mucoadhesive ability and a selective antagonism using the same and, more specifically, to a functional hydrated hyaluronic acid in which components fermented by lactic acid bacteria are captured in hyaluronic acid, which is a natural polymer substance, and a method for producing coated lactic acid bacteria using the same. The quadruply coated lactic acid bacteria coated using the functional hydrated hyaluronic acid according to the present invention is quadruply coated with a water-soluble polymer, a functional hydrated hyaluronic acid, a coating agent having porous particles, and a protein, thereby producing an excellent intestinal mucoadhesive ability, exhibiting an antibacterial action against deleterious bacteria in the intestines, and promoting growth of beneficial bacteria in the intestines.

Functional hydrated hyaluronic acid and method for producing coated lactic acid bacteria having excellent intestinal mucoadhesive ability and selective antagonistic action using same

RHT-3201 (KCTC 10833BP) conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases

Phtalazinone derivatives and manufacturing process thereof

Provided is aID9103 strain having accession number KCTC11818BP, and a method of producing hyaluronic acid by culturing the strain to produce hyaluronic acid having an average molecular weight of 10,000,000 Da or more.

[object Object]

The present invention relates to a buffer composition for promoting production of calcitriol or calcifediol, and a method for producing calcitriol or calcifediol using the same. More particularly, the present invention relates to a buffer composition for promoting production of calcitriol or calcifediol comprising a metallic compound, an organic solvent, cyclodextrin, tris(hydroxymethyl)aminomethane, sodium succinate, sodium chloride, magnesium chloride, and water, and a method for producing calcitriol or calcifediol using the same. In the method for producing calcitiriol or calcifediol, the production yield of calcitriol or calcifediol is high, and the bioconversion is carried out in an enzyme reaction system instead of in a microorganism culture system. Thus, it is not required to maintain a sterile state. Also, the separation/purification following the completion of a biocatalytic reaction can be carried out in a cleaner state than the microorganism culture method. Accordingly, there is an advantage in that a cost required for separation is low and the quality is improved. Furthermore, the buffer composition for promoting production of calcitriol or calcifediol can provide a high productivity of calcitriol or calcifediol.

Buffer composition for catalyzing the preparation of calcitriol or calcifediol and method for preparing calcitriol or calcifediol using same

Growing community of inventors

Seoul, South Korea

Jae-Hoon Kang